Capital International Ltd. CA Lowers Stock Position in The Cooper Companies, Inc. $COO

Capital International Ltd. CA lowered its position in The Cooper Companies, Inc. (NASDAQ:COO) by 9.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 103,691 shares of the medical device company’s stock after selling 10,433 shares during the period. Capital International Ltd. CA owned about 0.05% of Cooper Companies worth $8,499,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Root Financial Partners LLC grew its position in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares during the period. Bell Investment Advisors Inc grew its position in Cooper Companies by 106.3% during the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after buying an additional 219 shares during the period. True Wealth Design LLC grew its position in Cooper Companies by 484.8% during the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after buying an additional 383 shares during the period. Cromwell Holdings LLC grew its position in Cooper Companies by 128.8% during the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock valued at $40,000 after buying an additional 273 shares during the period. Finally, Board of the Pension Protection Fund bought a new position in Cooper Companies during the fourth quarter valued at about $41,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $67.34 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $13.14 billion, a PE ratio of 57.07, a P/E/G ratio of 1.74 and a beta of 0.87. The Cooper Companies, Inc. has a twelve month low of $58.89 and a twelve month high of $89.83. The company has a 50-day moving average price of $65.09 and a two-hundred day moving average price of $74.52.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.85%. The company’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter last year, the business earned $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Equities analysts forecast that The Cooper Companies, Inc. will post 4.63 EPS for the current year.

Analyst Ratings Changes

COO has been the subject of several research reports. Needham & Company LLC reduced their price target on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating for the company in a research report on Friday. Piper Sandler set a $86.00 price target on shares of Cooper Companies and gave the company an “overweight” rating in a research report on Monday, June 1st. Barclays increased their price target on shares of Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, March 6th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Wells Fargo & Company restated a “sell” rating and set a $66.00 price target (down from $82.00) on shares of Cooper Companies in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Cooper Companies has a consensus rating of “Hold” and an average target price of $82.64.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
• Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
• Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
• Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
• Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
• Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.